Interview med Michael Friis som opsummerer 2024, hvor Embla aktien har leveret bedre end det generelle marked og MedTech
Disclaimer: Embla Medical har en betalt digital IR-aftale med ProInvestor.com
Disclaimer: Embla Medical har en betalt digital IR-aftale med ProInvestor.com
9/12 2024 13:40 ProInvestorNEWS 3
123377 Prøv at kigge denne webcast igennem ved lejlighed. Det er en øjenåbner for hvad Emblas ortoser kan for mennesker med paralyseret lemmer som følge af blodprop, sklerose mv. De får mobiliteten tilbage:
https://media.ossur.com/video/upload/v1733508464/documents/corporate/presentations/Embla%20Medical%20-%20Neuro%20Orthotics%20%28Fior%20and%20Gentz%29%20-%20Virtual%20Group%20Call%20-%2003.12.2024.mp4
https://media.ossur.com/video/upload/v1733508464/documents/corporate/presentations/Embla%20Medical%20-%20Neuro%20Orthotics%20%28Fior%20and%20Gentz%29%20-%20Virtual%20Group%20Call%20-%2003.12.2024.mp4
9/12 2024 13:42 ProInvestorNEWS 3123378 Nordea 9/12-2024
Target price DKK 44.00
"Low penetration and attractive competitive situation With the penetration rate of high-function orthoses being well below 5% in developed markets, we see ample headroom for growth. The key competitor is Ottobock while other companies mainly target low-function products, creating an attractive duopolistic situation, in our view.
Plus the call highlighted that Fior & Gentz provides highly personalised treatment, and thanks to its unique configurator the company offers ~500,000 potential configurations. This, combined with the sales synergies, makes us believe that Fior & Gentz
Buy: Valuation still not demanding, in our view, despite solid run While the share is up 35% YTD, this on a par with EPS growth. Hence, it still trades at the low end of its historical 10-year multiple range"
Target price DKK 44.00
"Low penetration and attractive competitive situation With the penetration rate of high-function orthoses being well below 5% in developed markets, we see ample headroom for growth. The key competitor is Ottobock while other companies mainly target low-function products, creating an attractive duopolistic situation, in our view.
Plus the call highlighted that Fior & Gentz provides highly personalised treatment, and thanks to its unique configurator the company offers ~500,000 potential configurations. This, combined with the sales synergies, makes us believe that Fior & Gentz
Buy: Valuation still not demanding, in our view, despite solid run While the share is up 35% YTD, this on a par with EPS growth. Hence, it still trades at the low end of its historical 10-year multiple range"
10/12 2024 08:14 ProInvestorNEWS 2123390 Embla Medical får indledt dækning med "køb" af Intron Health
i dag kl. 07:47 ∙ MarketWire
Embla Medical
Embla Medical, der tidligere var kendt under navnet Össur, har fået indledt sin dækning med anbefalingen "køb" af finanshuset Intron Health.
Kursmålet for det islandske proteseselskab sættes i samme ombæring til 56 kr., skriver Bloomberg News.
Aktien steg mandag med 2,5 pct. til 36,90 kr., efter at Nordea løftede sit kursmål for aktien til 43,20 kr. fra 41 kr.
.\˙ MarketWire
i dag kl. 07:47 ∙ MarketWire
Embla Medical
Embla Medical, der tidligere var kendt under navnet Össur, har fået indledt sin dækning med anbefalingen "køb" af finanshuset Intron Health.
Kursmålet for det islandske proteseselskab sættes i samme ombæring til 56 kr., skriver Bloomberg News.
Aktien steg mandag med 2,5 pct. til 36,90 kr., efter at Nordea løftede sit kursmål for aktien til 43,20 kr. fra 41 kr.
.\˙ MarketWire
10/12 2024 08:35 ProInvestorNEWS 2123391 Rapporten fra Intron Health kan læses her.
241211_Embla_Medical_Initiation_St..
241211_Embla_Medical_Initiation_St..11/12 2024 06:14 ProInvestorNEWS 1123395 Embla i Mio-klubben https://www.euroinvestor.dk/podcast/millionaerklubben-10
